|
|
|
18.04.25 - 09:30
|
Sensorion Provides Preliminary Documents for the Combined Shareholders′ General Meeting of May 12, 2025 (Business Wire)
|
|
|
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announced that the Company's shareholders are invited to participate in the Combined General Meeting, to be held on Wednesday, May 12, 2025, at 2 pm CET in the premises of the hotel Square Louvois, located at 12, rue de Louvois, 75002, Paris, France.
The prior notice of meeting comprising the agenda and draft resolutions was published in the BALO (Bulletin des Annonces Légales Obligatoires) n°41 on April 4, 2025, and the convening notice shall be published in a newspaper empowered to publish legal notices on April 18, 2025.
The documents provided for in articles R.22-10-23 of the French Commercial Code, are available for consultation on the company's website mentioned below no later than the twenty-first day prior to the General Meeting: www.sensorion.com...
|
|
|
02.04.25 - 07:36
|
Sensorion Strengthens Leadership Team with Appointment of Amit Munshi as Chairman of the Board and Independent Director (Business Wire)
|
|
|
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announced the appointment of Amit Munshi, as Sensorion's independent director and Chairman of the Board, effective April 1, 2025. Mr. Munshi succeeds Mr. John Furey who stepped down as an Independent Board Member. Mr. Munshi is then appointed Chairman of the Board, replacing Khalil Barrage who served as the Company's interim Chairman since March 31, 2023. Mr. Barrage will continue to serve as a director on Sensorion's Board.
This appointment by the Board of directors is performed by way of co-optation, the mandate of Amit Munshi to replace John Furey will be submitted to Sensorion's shareholders for ratification at the Company's next General Meeting.
Khalil Barrage said: “On behalf of my fellow Board members and the management team, it's a pleasure to...
|
|
|
31.03.25 - 07:36
|
Sensorion Announces Webconference, in French, for its Retail Shareholders on April 7, 2025 (Business Wire)
|
|
|
Sensorion to host a webconference dedicated to its retail shareholders on April 7, 2025, in French, at 6.30pm CET (12.30pm ET)
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announced it will host a webconference for its retail shareholders on April 7, 2025, following its Full-Year 2024 release. The webconference will be held in French.
Sensorion's Chief Executive Officer, Nawal Ouzren, and management team, will host a webconference dedicated to its retail shareholders, in French, on April 7, 2025, at 6.30pm CET (12:30pm ET), to comment on the Company's latest announcements and outlook.
Click here to join the meetingMeeting ID: 338 799 647 078
Secret Code: Bi9wg2Py
You will also be able to join the webconference from Sensorion's website.
A replay of the webconference will be available on the Company's...
|
|
|
|
|
14.03.25 - 07:33
|
Sensorion Reports Full-Year 2024 Results, Provides Corporate Update and Announces Availability of Full-Year Report (Business Wire)
|
|
|
Enrolled first cohort into SENS-501's Phase 1/2 clinical trial, Audiogene, and received a positive DMC recommendation; enrollment of second cohort and KOL event to present new data expected during H1 2025
Primary and secondary endpoints achieved in SENS-401's Phase 2a Proof of Concept study for the preservation of residual hearing following cochlear implantation; business development discussions ongoing
End of enrollment in SENS-401's Phase 2a Proof of Concept study in Cisplatin-Induced Ototoxicity, NOTOXIS; topline data to be reported by end of Q4 2025
Strengthened balance sheet and shareholder registry via capital increases raising €65.5m from top tier U.S. and European healthcare dedicated institutional investors
Cash and short-term deposits of €77m finance the Company until end of Q1 2026
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat ...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
